Leboeuf, Rebecca <br/><br/>
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.  [electronic resource] 

 -  The Journal of clinical endocrinology and metabolism  Jun 2008 
 - 2194-201 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0021-972X 
<br/><br/><label>Standard No.: </label>10.1210/jc.2007-2825  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Benzamides--pharmacology<br/>Benzimidazoles--pharmacology<br/>Carcinoma--enzymology<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Diphenylamine--analogs & derivatives<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Humans<br/>Mice<br/>Mice, Nude<br/>Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors<br/>Mutation, Missense<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Substrate Specificity<br/>Thyroid Neoplasms--enzymology<br/>Xenograft Model Antitumor Assays